Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North ...

Pluribus is the antidote to 20 years of post-Lost mystery shows, and that's what makes it such a breath of fresh air

Okay, so the sensational pilot episode of Pluribus does open in mysterious fashion, to be fair. Researchers working at a ...

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today ...
eLife

SLC35G3 is a UDP-N-acetylglucosamine transporter for sperm glycoprotein formation and underpins male fertility in mice

SLC35G3-mediated UDP-GlcNAc transport is essential for proper sperm glycoprotein formation and male fertility.
Medscape

DNA Test Outshines PET for Lymphoma Prognosis

As PET scans fall short, blood-based circulating tumor DNA testing shows promise in monitoring large B-cell lymphoma ...
Applied Clinical Trials Online

FDA Approves UCB’s Kygevvi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

Kygevvi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...

Hallym University College of Medicine Professor Jaeyong Lee's Team Identifies Key Mechanism for Aging Suppression and Lifespan Extension

The research team led by Research Professor Jaeyong Lee at the Institute for Cellular Differentiation and Aging, College of Medicine, Hallym ...